Author:
Lu Li-Chun,Feng Gen-Sheng,Hsu Chih-Hung
Reference39 articles.
1. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028;Ott;J Clin Oncol,2019
2. Tissue-specific immunoregulation: A call for better understanding of the “immunostat” in the context of cancer;Pao;Cancer Discov,2018
3. Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases;van;Eur J Cancer,2013
4. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas;Chen;Oncologist,2012
5. Sustained systemic response paralleled with ovarian metastasis progression by sunitinib in metastatic renal cell carcinoma: Is this an anti-angiogenic potentiation of cancer?;Mete;Urol Ann,2015